Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.

PloS one - 1 Jan 2020

Cho Min-Sun, Park Chul Hwan, Lee Sungsoo, Park Heae Surng

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) is cell-free DNA that is released into peripheral blood by tumor cells. ctDNA harbors somatic mutations and mutant ctDNA obtained from blood can be used as a biomarker in advanced non-small cell lung cancer (NSCLC). In this study, we investigated the clinicopathological properties of tumors that shed ctDNA in surgically resected NSCLC patients. METHODS: Consecutive cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 32196518
DOI: 10.1371/journal.pone.0230622
PMCID: PMC7083310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.PMID 32196518Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read ↗

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read ↗

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Clinical Utility of ctDNA Analysis in Lung Cancer—A ReviewSemantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.Semantic proximity Read ↗

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.Semantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.